Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Last trade$1.65
Day change-$0.04 (-2.37%)
Day range$1.61 – $1.74
Volume25,719
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.86M
Price / earnings
—
Price / book
0.66×
Price / sales
—
EV / sales
—
EV / EBITDA
0.22×
Profitability
Earnings per share
-$8.26
Return on assets
-196.71%
Return on equity
-321.17%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.57×
Quick ratio
2.57×
Cash ratio
2.13×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$10.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ERNA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$1K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$1K
Selling, general and administrative
$1.12M
$1.31M
$1.63M
$1.42M
$958K
$1.37M
$1.42M
$1.54M
Research and development
$1.87M
$2.79M
$1.92M
$676K
$1.04M
$1.14M
$1.31M
$1.16M
Total operating expenses
$2.99M
$4.1M
$5.59M
$2.09M
$1.99M
$2.5M
$2.73M
$2.7M
Operating income
-$2.99M
-$4.1M
-$5.59M
-$2.09M
-$1.99M
-$2.5M
-$2.73M
-$2.7M
Interest expense
$49K
$55K
$0
-$27K
$31K
$0
$0
-$6.75M
Income before taxes
-$2.94M
-$4.01M
-$5.55M
-$1.56M
-$1.23M
-$3.14M
-$8.19M
-$5.75M
Income taxes
$0
$0
-$40K
-$62K
$6K
$3K
$8K
$11K
Net income
-$2.94M
-$4.01M
-$5.51M
-$1.5M
-$1.24M
-$3.14M
-$8.2M
-$5.76M
Net income attributable to common shareholders
-$2.94M
-$4.02M
-$5.51M
-$1.51M
-$1.24M
-$3.15M
-$8.2M
-$5.77M
EBITDA
-$2.98M
-$4.1M
-$3.54M
-$1.88M
-$1.98M
-$2.48M
-$2.71M
-$1.18M
Basic earnings per share
-$1.89
-$3.40
-$6.95
-$4.56
-$3.77
-$15.19
-$57.76
-$56.38
Diluted earnings per share
-$1.89
-$3.40
-$6.95
-$4.56
-$3.77
-$15.19
-$57.76
-$56.38
Recent news
Company coverage with links to the original publishers.
Ernexa Therapeutics (NASDAQ: ERNA) announced the pricing of a $10.5 million public offering of 21 million shares at $0.50 per share, along with warrants to purchase up to 21 million shares at $0.68 exercise price. The company plans to use proceeds to advance its cell therapy development programs, particularly ERNA-101 for ovarian cancer treatment. The offering is expected to close on February 10, 2026.
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna’s Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna’s common stock (the “Stock Option”) to its new President and Chief Executive Officer, Sanjeev Luther, effective January 1, 2024, the first date of his employment. The Stock Option was granted pursuant to the terms of Mr. Luther’s employment agreement and as a material inducement to his joining Eterna as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.